AZN
Price
$73.50
Change
+$2.57 (+3.62%)
Updated
Feb 6, 01:57 PM (EDT)
Capitalization
208.98B
Earnings call today
LLY
Price
$860.30
Change
+$18.12 (+2.15%)
Updated
Feb 6, 11:31 AM (EDT)
Capitalization
739.66B
Earnings call today
Ad is loading...

AZN vs LLY

Header iconAZN vs LLY Comparison
Open Charts AZN vs LLYBanner chart's image
AstraZeneca
Price$73.50
Change+$2.57 (+3.62%)
Volume$2.5K
Capitalization208.98B
Eli Lilly & Co
Price$860.30
Change+$18.12 (+2.15%)
Volume$5.76K
Capitalization739.66B
AZN vs LLY Comparison Chart
Loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AZN vs. LLY commentary
Feb 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a StrongBuy and LLY is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 06, 2025
Stock price -- (AZN: $70.93 vs. LLY: $842.18)
Brand notoriety: AZN and LLY are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AZN: 153% vs. LLY: 123%
Market capitalization -- AZN: $208.98B vs. LLY: $739.66B
AZN [@Pharmaceuticals: Major] is valued at $208.98B. LLY’s [@Pharmaceuticals: Major] market capitalization is $739.66B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AZN’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s).

  • AZN’s FA Score: 2 green, 3 red.
  • LLY’s FA Score: 2 green, 3 red.
According to our system of comparison, LLY is a better buy in the long-term than AZN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AZN’s TA Score shows that 5 TA indicator(s) are bullish while LLY’s TA Score has 6 bullish TA indicator(s).

  • AZN’s TA Score: 5 bullish, 4 bearish.
  • LLY’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, LLY is a better buy in the short-term than AZN.

Price Growth

AZN (@Pharmaceuticals: Major) experienced а +0.98% price change this week, while LLY (@Pharmaceuticals: Major) price change was +4.74% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.36%. For the same industry, the average monthly price growth was +0.34%, and the average quarterly price growth was -7.84%.

Reported Earning Dates

AZN is expected to report earnings on Apr 29, 2025.

LLY is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.36% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LLY($740B) has a higher market cap than AZN($209B). LLY has higher P/E ratio than AZN: LLY (131.13) vs AZN (35.30). LLY YTD gains are higher at: 9.091 vs. AZN (8.265). AZN has higher annual earnings (EBITDA): 13.4B vs. LLY (8.57B). AZN has more cash in the bank: 5.86B vs. LLY (2.93B). LLY has less debt than AZN: LLY (25.2B) vs AZN (28.6B). AZN has higher revenues than LLY: AZN (45.8B) vs LLY (34.1B).
AZNLLYAZN / LLY
Capitalization209B740B28%
EBITDA13.4B8.57B156%
Gain YTD8.2659.09191%
P/E Ratio35.30131.1327%
Revenue45.8B34.1B134%
Total Cash5.86B2.93B200%
Total Debt28.6B25.2B113%
FUNDAMENTALS RATINGS
AZN vs LLY: Fundamental Ratings
AZN
LLY
OUTLOOK RATING
1..100
1718
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
89
Overvalued
PROFIT vs RISK RATING
1..100
306
SMR RATING
1..100
5216
PRICE GROWTH RATING
1..100
5348
P/E GROWTH RATING
1..100
6087
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZN's Valuation (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for LLY (89). This means that AZN’s stock grew somewhat faster than LLY’s over the last 12 months.

LLY's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is in the same range as AZN (30). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.

LLY's SMR Rating (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for AZN (52). This means that LLY’s stock grew somewhat faster than AZN’s over the last 12 months.

LLY's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as AZN (53). This means that LLY’s stock grew similarly to AZN’s over the last 12 months.

AZN's P/E Growth Rating (60) in the Pharmaceuticals Major industry is in the same range as LLY (87). This means that AZN’s stock grew similarly to LLY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AZNLLY
RSI
ODDS (%)
Bearish Trend 2 days ago
50%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
46%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
72%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 11 days ago
54%
Bullish Trend 2 days ago
68%
Declines
ODDS (%)
Bearish Trend 3 days ago
45%
Bearish Trend 4 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bullish Trend 2 days ago
53%
Bearish Trend 2 days ago
58%
View a ticker or compare two or three
Ad is loading...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XOMA26.340.62
+2.41%
XOMA Royalty Corporation
BNT59.220.78
+1.33%
Brookfield Wealth Solutions Ltd
FAST73.540.35
+0.48%
Fastenal Company
CYTH0.80N/A
+0.39%
Cyclo Therapeutics
PLYA12.88N/A
N/A
Playa Hotels & Resorts NV

LLY and

Correlation & Price change

A.I.dvisor indicates that over the last year, LLY has been loosely correlated with NVS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LLY
1D Price
Change %
LLY100%
+1.95%
NVS - LLY
42%
Loosely correlated
+4.11%
OGN - LLY
25%
Poorly correlated
+2.34%
AZN - LLY
24%
Poorly correlated
+2.86%
JNJ - LLY
21%
Poorly correlated
+0.78%
ABBV - LLY
21%
Poorly correlated
+0.95%
More